Cormedix Inc. ((CRMD)) has held its Q1 earnings call. Read on for the main highlights of the call.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cormedix Inc.’s latest earnings call struck an optimistic tone as management highlighted robust revenue growth, expanding margins, and a strengthened balance sheet alongside progress in its anti-infective pipeline. Executives acknowledged reimbursement uncertainties and clinical trial delays, but emphasized that strong DefenCath adoption, a successful REZZAYO Phase III readout, and raised guidance collectively support a bullish outlook for the coming years.
Blowout Quarter Showcases Revenue Surge and Margin Expansion
Cormedix reported Q1 2026 net revenue of $127.4 million, more than tripling the $39.1 million recorded a year earlier as DefenCath and the Melinta portfolio drove the top line. Adjusted EBITDA jumped to $70 million from $23.6 million, underscoring significant margin expansion and reinforcing the company’s message that its core operations are scaling efficiently.
Upgraded Outlook Signals Confidence in 2026 Trajectory
On the back of its strong start, management raised full-year 2026 net revenue guidance to a range of $325 million to $345 million, up from $300 million to $320 million previously. Adjusted EBITDA is now projected between $115 million and $135 million, while DefenCath revenue expectations rose meaningfully to $175 million to $195 million, suggesting sustained momentum in its flagship product.
DefenCath Adoption Accelerates Across Key Dialysis Networks
DefenCath generated $97.5 million in Q1 sales, driven by what management described as durable utilization growth and rising customer run rates versus the prior quarter. Major dialysis providers, including U.S. Renal Care, IRC, and Fresenius, have reported positive real-world outcomes, helping to cement clinical adoption and supporting the company’s thesis that DefenCath can reduce infection-related complications.
REZZAYO Phase III Win Broadens Anti-Fungal Opportunity
Top-line data from the ReSPECT Phase III trial showed REZZAYO achieved non-inferior fungal-free survival at day 90 compared with standard therapy, with rates of 60.7% versus 59.0%. The study met its primary endpoint across Candida, Aspergillus, and nosocomial pathogens and reported favorable safety signals, with a supplemental filing targeted in the second half of 2026 and a potential commercial launch penciled in for 2027.
Cash Generation and Buybacks Underline Financial Flexibility
Cormedix ended the quarter with $178.1 million in cash after generating $42.4 million from operations, even as it paid sizable incentive rebates. Cash increased by $33.3 million during the period, and the company repurchased $11.1 million of its own shares, reinforcing management’s message that it can fund growth initiatives while returning capital to shareholders.
Melinta Acquisition Bolsters Diversification and Growth
The Melinta acquisition, completed in August 2025, contributed $29.9 million in revenue during the quarter and expanded Cormedix’s anti-infective portfolio. Management highlighted that the acquired assets, including BARDA-supported pediatric and biodefense programs, provide both incremental revenue and longer-term pipeline options beyond DefenCath.
TDAPA Expiration Poses Near-Term Reimbursement Headwinds
Management cautioned that the expiration of TDAPA reimbursement at the end of June 2026 will introduce DefenCath revenue volatility in the back half of the year as CMS transitions to a new add-on framework. Executives anticipate price erosion in the third and fourth quarters of 2026 but stressed that protecting and growing patient utilization will be the top priority during the transition period.
Q2 to Be Distorted by Shelf Stock Adjustment
Investors were warned that the second quarter will effectively behave like a two-month period because of an expected four-week shelf stock adjustment at Cormedix’s largest customer. Management estimates Q2 DefenCath revenue at about $60 million, plus or minus a few million, and noted that Q1 benefited from a nonrecurring $9 million favorable change in sales estimates.
TPN Program Delays Push Potential Launch Further Out
The company’s NUTRI-GAURD (TPN) Phase III program remains only about one-third enrolled toward its interim target, reflecting lower-than-expected infection rates and recruitment challenges. Cormedix now projects completion around 2028 and is planning protocol changes and new sites, including five in Turkey, which may require a revised statistical plan and underscore the longer investment horizon for this asset.
Non-Operating Charges Cloud GAAP Earnings Picture
Approximately $25 million in non-operating expenses tied to mark-to-market adjustments on marketable securities and contingent consideration weighed on reported net income, complicating the headline earnings story. Management reminded investors that while the GAAP tax rate sits near 28%, cash taxes may be lower due to net operating losses, though the statutory rate still governs reported results.
Rising Operating Costs Reflect Expanded Scale and Investments
Operating expenses rose to $41.5 million in the quarter, including $7.2 million for R&D, $12.5 million for sales and marketing, and $21.7 million for G&A, reflecting the larger combined organization post-Melinta. The company guided full-year cash operating expenses to $145 million to $160 million and pointed to higher personnel, commercial infrastructure, and branded prescription fees as the main drivers.
Medicare Mix and Contracting Shape Future Upside
Cormedix noted that over 90% of DefenCath patients are in Medicare fee-for-service, highlighting a heavy reliance on this payer channel. Management views Medicare Advantage contracting as a meaningful upside lever, but acknowledged that limited near-term penetration means incremental growth will depend on successful negotiations rather than immediate volume gains.
Guidance Reflects Growth Ambition Amid Reimbursement Risk
Looking ahead, the company’s raised guidance assumes net revenue between $325 million and $345 million and adjusted EBITDA between $115 million and $135 million, supported by DefenCath revenue of $175 million to $195 million. The outlook also bakes in $145 million to $160 million of cash operating expenses, the addition of 15 to 20 commercial and medical hires in the second half, and potential DefenCath variability after TDAPA expiration, while explicitly excluding upside from new customer wins or Medicare Advantage.
Cormedix’s earnings call portrayed a company riding strong product momentum and expanding profitability, yet bracing for reimbursement and clinical development challenges. For investors, the story hinges on whether DefenCath’s utilization growth and REZZAYO’s path to market can offset near-term pricing pressure and trial delays, but management’s raised guidance and cash position suggest they are confident in delivering continued value.